- Home
- J vs ROIV Comparison
J vs ROIV Comparison
Compare J & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | J | ROIV |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | J | ROIV |
|---|---|---|
| Price | $134.79 | $20.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $155.90 | $21.19 |
| AVG Volume (30 Days) | 1.4M | ★ 5.9M |
| Earning Date | 11-20-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $12,029,783,000.00 | $20,329,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.38 | $376.94 |
| P/E Ratio | $56.75 | ★ N/A |
| Revenue Growth | ★ 4.60 | N/A |
| 52 Week Low | $106.23 | $8.73 |
| 52 Week High | $168.44 | $21.48 |
Technical Indicators
Market Signals| Indicator | J | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 52.88 |
| Support Level | $132.75 | $19.96 |
| Resistance Level | $143.16 | $21.48 |
| Average True Range (ATR) | 5.05 | 0.54 |
| MACD | 0.46 | -0.15 |
| Stochastic Oscillator | 35.29 | 25.41 |
Price Performance
Historical ComparisonAbout J Jacobs Solutions Inc.
Jacobs Solutions is a global provider of engineering, design, procurement, construction, and maintenance services as well as cyber engineering and security solutions. The firm serves industrial, commercial, and government clients in a wide variety of sectors, including water, transportation, healthcare, technology, and chemicals. Jacobs Solutions employs approximately 60,000 workers. The company generated $11.5 billion in revenue in fiscal 2024.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.